As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.
8 Analysts have issued a Kazia Therapeutics Ltd Sponsored ADR forecast:
8 Analysts have issued a Kazia Therapeutics Ltd Sponsored ADR forecast:
Dec '24 |
+/-
%
|
||
Revenue | 1.53 1.53 |
7,550%
7,550%
|
|
Gross Profit | - - |
-
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -20 -20 |
55%
55%
|
Net Profit | -19 -19 |
81%
81%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Kazia Therapeutics Ltd. engages in the pharmaceutical drug research and development. Its pipeline includes two clinical-stage drug development candidates such as GDC-0084, and Cantrixil. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.
Head office | Australia |
CEO | John Friend |
Employees | 13 |
Founded | 1994 |
Website | www.kaziatherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.